Enanta Pharmaceuticals | ENTA - Trade Debtors


Enanta Pharmaceuticals reported $40.16M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
AstraZeneca USD 17.88B 1.17B Mar/2026
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Biogen USD 1.79B 76.6M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Gilead Sciences USD 4.91B 182M Dec/2025
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Immunic USD 333K 156K Dec/2025
Incyte USD 1.05B 27.09M Mar/2026
Insmed USD 140.86M 75.6M Dec/2025
Ionis Pharmaceuticals USD 74M 8M Mar/2026
J&J USD 21.33B 3.72B Dec/2025
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
Merck USD 11.78B 345M Dec/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Novavax USD 106.45M 72.27M Dec/2025
Pfizer USD 15.84B 2.27B Dec/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026